Shailaja Suryawanshi

Statistics

Publications

Citations

6.1K

H-Index

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Maryland, Baltimore

University of California, San Francisco

St. Michael's Hospital

University of Toronto

Shailaja Suryawanshi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and clinical pharmacology.

Publications per year

1998–2021

Publications

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima, Manish A. Shah, Kei Muro et al. · Journal of Clinical Oncology · 2020 · 1.2K citations

Medicine, Oncology, Pharmacotherapy +17

Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial

Dennis M. Black, Desmond Thompson, Douglas C. Bauer et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 980 citations · Full text

Medicine, Orthopedic Surgery, Bone Metabolism +12

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension

Kristine E. Ensrud, Elizabeth Barrett‐Connor, Ann V. Schwartz et al. · Journal of Bone and Mineral Research · 2004 · 277 citations

Medicine, Pharmacotherapy, Bone Augmentation +16

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

Ngozi Erondu, Ira Gantz, Bret J. Musser et al. · Cell Metabolism · 2006 · 184 citations · Full text

Agriculture, Nutrition, Clinical Nutrition +13

1–5 of 23